Navigation Links
FDA to Review Potential New Use of XGEVA® (Denosumab) at Oncologic Drugs Advisory Committee Meeting
Date:12/29/2011

ogists and oncologists to prevent SREs in patients with bone metastases from solid tumors.

XGEVA is a fully human monoclonal antibody that binds to RANK Ligand, a protein essential for the formation, function and survival of osteoclasts (the cells that break down bone). XGEVA prevents RANK Ligand from activating its receptor, RANK, on the surface of osteoclasts, thereby decreasing bone destruction.

XGEVA has been studied in over 7,000 patients with cancer. In clinical trials, XGEVA demonstrated a clinically meaningful improvement compared to the previous standard of care in preventing bone complications. XGEVA is also being investigated for the potential use to delay the onset of bone metastasis in adjuvant breast cancer.

XGEVA Important Safety Information

XGEVA can cause severe hypocalcemia. Correct pre-existing hypocalcemia prior to XGEVA treatment. Monitor calcium levels and administer calcium, magnesium and vitamin D as necessary. Advise patients to contact a healthcare professional for symptoms of hypocalcemia.

Osteonecrosis of the jaw (ONJ) can occur in patients receiving XGEVA. Patients who are suspected of having or who develop ONJ while on XGEVA should receive care by a dentist or an oral surgeon. In these patients, extensive dental surgery to treat ONJ may exacerbate the condition.

The most common adverse reactions in patients receiving XGEVA were fatigue/asthenia, hypophosphatemia and nausea. The most common serious adverse reaction in patients receiving XGEVA was dyspnea. The most common adverse reactions resulting in discontinuation of XGEVA were osteonecrosis and hypocalcemia. Please visit www.amgen.com or www.xgeva.com for full U.S. prescribing information.

XGEVA Regulatory Status

XGEVA has been approved in the U.S., Canada, the European Union (EU), Switzerland, Australia and Russia for the prevention of SREs i
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity
2. Bipartisan Group of 22 House Members ask CMS to Stop Prepayment Review Project that would Jeopardize Care for Medicare Beneficiaries
3. Anthera Announces Completion of Safety Review by DSMB for VISTA-16
4. Homecare Providers and Consumer Advocates Urge Congress to Stop Ineffective Medicare Payment Review Process for Mobility Equipment
5. M&A Surges, Companion Diagnostics Accelerate, and Early Detection Offers New Prospects, Finds PwCs Biennial Review of the In Vitro Diagnostics Industry
6. Physicians Capital Investments Announces Pedro Vergne-Marini, MD Named to Beckers ASC Review "350 People in the ASC Industry to Know"
7. Avreo Previews Version 7 RIS/PACS at RSNA
8. Futuremed and Cardinal Health Canada Inc. Report on Developments in Competition Bureau Review of the Proposed Acquisition
9. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
10. U.S. Food and Drug Administration (FDA) Delays Review of Takedas Investigational Type 2 Diabetes Therapies, Alogliptin and Alogliptin/Pioglitazone
11. Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... and ,S-HERTOGENBOSCH, The Netherlands , ... subsidiary, HealthLink International received its ISO 13485 certificate for ... and administrative services for medical device manufacturers throughout ... Rick Hughes , President of HealthLink Europe and ... 13485 certified facilities, two in Europe ...
(Date:4/1/2015)... April 1, 2015  New York College of Health ... Intellectual Properties portfolio with U.S. Patent #8,996,098 donated by ... patent represents a surgical instrument that allows surgeons to ... it were in the traditional format of a slide ... medical databases during surgery, thus providing the surgeon real ...
(Date:4/1/2015)... YORK , April 1, 2015 Morgan ... claims against the board of directors of Auspex Pharmaceuticals, ... concerning possible breaches of fiduciary duty and other violations ... Company to Teva Pharmaceuticals Industries Ltd.  The transaction is ... own shares of Auspex and would like to learn ...
Breaking Medicine Technology:Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 2Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 3
... Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) ... VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, ... Phase 3 studies in patients with macular edema due ... 56.1 percent of patients receiving VEGF Trap-Eye 2 milligrams ...
... N.Y., Dec. 20, 2010 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... teleconference and webcast at 8:30 a.m. Eastern Time on Monday, ... study with VEGF Trap-Eye in central retinal vein occlusion (CRVO) ... DA VINCI study in patients with diabetic macular edema (DME). ...
Cached Medicine Technology:Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 2Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 3Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 4Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 5Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 6Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 7Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 8Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 9Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME) 2
(Date:4/2/2015)... Portsmouth, New Hampshire (PRWEB) April 02, 2015 ... the availability of ForMedical Cloud services, a comprehensive ... for use by home health care service organizations. ... a single source solution for the provisioning and ... a high quality and competitively positioned home health ...
(Date:4/2/2015)... 02, 2015 Deerfield Veterinary Hospital ... accreditation from the American Animal Hospital Association (AAHA). ... to 15 percent of veterinary practices in the ... hospitals are not required by law to be ... examined the Springfield veterinary hospital  on some ...
(Date:4/2/2015)... Atlanta, Georgia (PRWEB) April 02, 2015 ... continued the Lunch Seminar Series on March 30th ... Director of PartnerTech Inc. , a leading provider ... ‘Total Cost Thinking: Defining Total Cost vs. Piece ... late-stage configuration, agile supply chain service and other ...
(Date:4/2/2015)... “ SmartenFit ” was featured on NewsWatch ... at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... for a sustainable healthy lifestyle. , Health and fitness apps ... new application that covers health from a different angle. The ...
(Date:4/2/2015)... 02, 2015 Zapable - a new ... a quick and easy means for creating professional mobile ... creating a buzz of excitement throughout the Internet marketing ... attention of HonestyFirstReviews.com’s Tiffany Hendricks, prompting her to publish ... Andrew and Chris Fox's new Zapable software has ...
Breaking Medicine News(10 mins):Health News:ChartaCloud Introduces ChartaCares and ForMedical Cloud Services for Home Health Care 2Health News:Deerfield Veterinary Hospital Earns Renewed AAHA Accreditation 2Health News:Georgia Tech Manufacturing Institute Lunch Series Continues with Gary Bruce of PartnerTech 2Health News:Georgia Tech Manufacturing Institute Lunch Series Continues with Gary Bruce of PartnerTech 3Health News:An Application for Long Term Sustainable Lifestyle Change Was Featured on NewsWatch Television 2Health News:Zapable - Review Examining Andrew and Chris Fox’s App Building Software System Released 2
... price for a 30-second advertising spot in the 2012 Super Bowl ... study suggests that, for advertisers, it may not really matter if ... But for the sake of companies forking out big bucks on ... The study by an Oregon State University researcher, which is ...
... -- Teens who think of themselves as thrill-seekers and who ... likely to drive with other teens in the car, which ... finds. And a second study of teens involved in ... distraction and risky driving behavior often played a role. ...
... HealthDay Reporter , THURSDAY, Jan. 26 (HealthDay News) -- ... provide insight into whether patients are at high risk of ... cancer. The test, which is currently available, could ... prevent the cancer from returning. There are caveats: The ...
... a "common sense" decision to start the company in a ... belt. , "We wanted to give better stroke care," said ... of Neurology at the Medical College of Georgia at Georgia ... and his colleagues were frustrated that nearly five years after ...
... By Denise Mann HealthDay Reporter , THURSDAY, Jan. ... for liver cancer among people with hepatitis B, a new study ... hepatitis B virus, is one of the main causes of liver ... have shown promise in reducing risk for cancer. Other studies have ...
... a sensitive non-invasive marker of early lung disease in young ... from Australian researchers. "We found that LCI is elevated ... airway inflammation and Pseudomonas aeruginosa," said Yvonne Belessis, MBBS, MPH, ... may not only be a marker of early CF lung ...
Cached Medicine News:Health News:Sporting event ads viewed favorably - especially if the game is close 2Health News:Teen Driver's Friends Can Be Dangerous Distraction, Studies Find 2Health News:Test Might Predict Risk of Lung Cancer's Return 2Health News:Georgia Bio honors biotech company that enables stroke care 2Health News:Georgia Bio honors biotech company that enables stroke care 3Health News:Statins May Stave Off Liver Cancer in People With Hepatitis B 2Health News:Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index 2
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: